{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"data_sharing_plan":["IPD Sharing (as of February 2023): No"],"condition":["Renal Cell Carcinoma (RCC)","Colorectal Cancer (CRC)","Lung Cancer","NSCLC","UC (Urothelial Cancer)","Gastric Cancer","Head and Neck Cancer","Carcinoma, Renal Cell","Mesothelioma","Bladder Cancer","Metastatic Cancer","Solid Tumors"],"disease":["Renal Cell Carcinoma (rcc)","Colorectal Cancer (crc)","Lung Cancer","Nsclc","Gastric Cancer","Carcinoma, Renal Cell","Mesothelioma","Bladder Cancer","Head And Neck Cancer","Metastatic Cancer","Uc (urothelial Cancer)","Solid Tumors"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2225246"],"location":["Netherlands","United States","Italy","Spain"],"study_start_month":["9"],"keyword":["Tumor Metabolism","Immune Therapy","Programmed cell death protein-1 (PD-1) inhibitor","Immuno-Oncology","SCCHN","Arginase","GEJ","Pembrolizumab","RCC","Programmed death ligand 1 (PD-L1) inhibitor","Checkpoint Inhibitors","Arginase Inhibitor","MEL","INCB001158 (CB-1158)"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors","description":"This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.","dates":{"creation":"2016-09-15"},"accession":"2225246","cross_references":{"ClinicalTrials___gov":["NCT02903914"]}}